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In previous work we have indicated the potential use of polymers of poly- 
glutamic  acid  as  plasma  volume expanders,  calling attention  to  the  unique 
advantages offered by these polyelectrolytes for this purpose (1,  2).  Particu- 
larly important in this connection are (a) the enhanced oncotic potency con- 
ferred on these compounds by the Donnan effects associated with the highly 
ionized molecule, and (b) the opportunity of altering the size and shape of the 
molecule to fit the requirements of blood stream retention, without qualitatively 
changing  its  composition. The  necessity  for  exploiting  the  latter  property 
became apparent when it was demonstrated that linear polyglutamyl peptide 
of 15,000 molecular weight, with molecular length approximately equal to that 
of serum albumin but narrower in diameter, and even linear peptides of molecu- 
lar weight up to 120,000 were rapidly excreted in human beings via the kidney 
(3).  Methods  of polymerizing these  peptides  in  such  fashion  as  to  increase 
their diameter were developed, and  the products  formed were demonstrated 
to be characterized by increased blood stream retention in human beings (2). 
Further work has been directed  toward  the development of a  molecule of 
dimensions that would function as a plasma extender with a half-life of 15 to 20 
hours in humans. Many polymers have been made and tested for this purpose. 
Finally, a  group which are in the proper range has been produced. The results 
of the clinical tests with this group, and pertinent data on some of their physico- 
chemical properties relating to their oncotic efficiency, form the subject of this 
report. 
Materials and Methods 
The starting peptide  x was prepared from a deep culture filtrate of Bacillus subtilis, and 
purified by previously  described  methods (4, 2). 
Preparation of Backbone Peptide.--The number average molecular  weight of different lots 
of this starting peptide usually ranged from 30,000 to 100,000. By suitable fractionation of 
We are indebted to Merck and Company, Inc., of Rahway, New Jersey, for providing 
this starting peptide and some of the side chain esters used for this work. 
667 668  GLUTAMYL PEPTIDE  POLYMERS 
this material, backbone of desired size can be obtained. The precise details of fractionation 
varied somewhat with the lot of the starting material, but the general procedure employed 
was similar for all samples. A  typical example is as follows: To 12 liters of a  2.5 per cent 
solution of the sodium salt of 34,000 number average molecular weight peptide in 0.6 molar 
sodium chloride solution, pH 6:5,  5.0 liters of 95 per cent ethyl alcohol was added with stir- 
ring. On standing overnight at 0°C., a heavy oil, containing high molecular weight peptide, 
separated out and settled to the bottom of the container. The supernatant was siphoned off 
and 300 ml. of ethyl alcohol added to it. On standing overnight in the cold room a  second 
cut was obtained by another heavy oil. The supernatant was separated by decantation. This 
second oil was diluted with water to make a 4 per cent solution of peptide and sufficient hy- 
drochloric acid  was added  to make the final acid  concentration half normal. The peptide 
precipitated out on  standing overnight in  the  cold  room  and was  collected  by  filtration, 
washed with water, alcohol and ether, and dried in vacuo. It is sometimes advantageous to 
remove coloring matter by treatment with charcoal prior to acidification. The supernatant 
of the second oil contains low molecular weight peptide which may be recovered by addition 
of more alcohol. In this fractionation the following yields were obtained: 143 gin. of 72,000 
molecular weight, 50 gin. of 48,000 molecular weight, and 50 gin. of 30,000 molecular weight. 
The middle cuts were used as backbones and  these fractions were  more precisely  char- 
acterizod with respect  to  size  by an  alcohol fractionation similar to  the above in which, 
however, the alcohol concentrations were so adjusted that the first and third fractions each 
represented 5 to 10 per cent of  the  total.  The molecular weights of  these small fractions 
essentially constitute the upper and lower limits of the backbone molecular weight. 
Preparations  of Side  Chains.--The  side  chains  were  prepared  for  conjugation  as  the 
methyl  esters. Purified  peptide of 12,000  to 15,000  molecular weight was suspended in 7 N 
dry methanolic HCI, using 2  liters of solvent per 100 gin. of peptide, and the mixture was 
allowed to stand at room temperature for 10 hours with occasional shaking. After a  few hours 
the peptide went completely into solution. As much as possible of the methanol and HCI 
was removed by vacuum distillation for 10 hours at room temperature. The remaining thick 
viscous solution of polyester was converted to a  dry white powder by a few ether precipita- 
tions from  methanol.  This powder  was  extracted  with pyridine  and  the  pyridine-soluble 
portion was used for conjugation. 
Preparation and Puriflvation of Polymer.--The conjugation and saponification of conju- 
gate were carried out as previously described (2). After saponification unreacted side chain 
was  separated  from conjugate by alcohol fractionation. To  the crude neutralized solution 
of saponified conjugate at pH 7.0 was added sufficient sodium chloride and 95 per cent etha- 
nol to make the final concentrations 0.6 ~  and 40 per cent respectively. On standing over- 
night at 0°C.  the sodium salt of conjugate separated out as a  heavy oil. After decantation 
of  the  supernatant, which contained  the unreacted  side  chain,  the  conjugate  bearing oil 
was diluted and similarly reprecipitated twice more. The final oil contained very little un- 
reacted side chain as evidenced by the concentration of free amino groups which were deter- 
mined by the use of Sanger's reagent on a suitable aliquot. On lyophilizing the oil to remove 
alcohol, the sodium salt was left as a  water-soluble white solid. This was dissolved in saline 
and final concentrations were adjusted to 0.85 per cent with respect to sodium chloride and 
2.0 to 2.5 per cent with respect to conjugate. The pH was adjusted to 7.2. The solution was 
sterilized by Seitz filtration and tested for sterility and pyrogenicity before use. 
The patients tested were all admitted to the hospital for conditions unrelated to the cir- 
culatory or renal systems, and all had normal renal and cardiac function. All had been afe- 
brile throughout their hospital stay prior to the test, except for one patient with Hodgkin's 
disease whose afternoon temperature usually rose to 99-100°F.  During the day of the test 
the patients were kept on a  low calorie, fat-free diet. Red cell counts and hematocrit deter- ROSENTHAL~ O'CONNELL~ AXELROD~ AND  BOVARNICK  669 
minations were performed by standard methods. White cell counts and differential counts 
were done with the previously described slight modification of the customary method  (3). 
Clotting time was determined by a modified Lee White method (5). The bleeding time was 
determined by the Duke method (6). 
Plasma volumes were determined by the Evans blue due method (7) or by plasma pro- 
rein dilution or both.  When the former method was used the determination was based on 
samples taken at 10, 20, and 30 minute intervals after injection of the dye. In many control 
trials plasma volumes obtained before, and 1 and 6 hours after a  1 liter infusion of saline 
fell within a  150 ml. spread. Plasma proteins were determined by Kjeldahl nitrogen analy- 
ses of the dissolved (in 2 N NaOH)  washed, trichloracetic acid precipitate  of heparinized 
plasma samples. Concentration  of the polymer in plasma was determined by the method 
previously described (8). 
The molecular weight of the conjugate was determined by osmometry using the haLf-sum 
method of Fuoss and Mead in a modified Fuoss-Mead osmometer (9, 10). Osmotic pressures 
of varying concentrations of conjugate in 1.0 M  sodium chloride solution, pH 5.5, were meas- 
ured at 25.00 ±0.01°C. A wet gel cellophane membrane, No. 450, was used.  2 Cathetometer 
readings for both positive and negative applied pressures were taken at 10 minute intervals 
over a period of 2~ hours each. The maximum applied pressures did not exceed 3 cm from 
equilibrium pressure. In all cases the last  three  of the series of readings were essentially 
identical. 
Osmotic pressures of polymer and of serum albumin-polymer  mixtures were determined 
in a simple osmometer consisting of a Visking tubing tied at one end and plugged at the 
other by a two holed rubber stopper bearing a capillary tube and a filling outlet. The solutes 
were dissolved in isotonic saline at pH 7.2. After loading, equilibrium was obtained by ro- 
tating the osmometer in a 100-fold volume of saline for 12 hours at room temperature. Read- 
ings were then taken for a period of 12 to 24 hours with the osmometer in a constant tem- 
perature  air bath.  A measured capillary correction and a density correction were applied, 
and the values obtained were corrected to 25°C. 
RESULTS AND DISCUSSION 
Of the many peptides and polymers tested,  the group shown in Table I  in 
many ways provides the most promising basis for further development. It is 
evident from the data that two of the polymers, Nos. 55  and 59,  gave satis- 
factory sustained plasma expansion. The 6 hour volume retention of these two 
were 75 and 90 per cent of their respective 1 hour retention volumes. For an 
expander with a  volume retention half-life of  15  hours,  the calculated value 
is 79 per cent retention in 5  hours if the rate of disappearance follows a  first 
order reaction. The use of the 1 hour retention volume as a base llne rather than 
the infusion volume is due to the fact that the infusion volumes in this explora- 
tory series were  necessarily somewhat arbitrary. It is therefore felt  that  the 
1  hour volume expansion provides a  more  valid base  line for  evaluation of 
subsequent volume retention than does the actual volume injected. 
While it  is  recognized  that  the  data  in no  sense  adequately characterize 
these conjugates with respect to molecular dimensions, they do provide on a 
comparative basis reasonably good clues as  to  the  size  of  components which 
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are apt to yield a satisfactory product under the conditions of conjugation used 
in  this work. Thus it is seen conjugates 55 and  59 both have backbones of 
number  average  molecular  weights  higher  than  40,000  and  side  chains  of 
greater than 3,000. It is evident that shortening the side chain,  conjugate 58, 
or the backbone, conjugates 51  and 52,  and possibly 56,  seems to lead to a 
loss of ability to effect satisfactory retention of plasma volume expansion. 
These findings  are more or less substantiated by the data on plasma levels 
and  urinary  excretion of the polymers (Table H). The rate  of clearance  of 
polymer from the blood stream as evidenced by the percentage decrease in the 
total  plasma  polymer between  1 and  6  hours  post infusion  was slower  for 
polymers 59 and 55, and more rapid for polymers 51, 52, 57, and 58. 
TABLE I 
Plasma Volume  Expansion by Various Sized Polymers 
Polymer 
51 
52 
55 
56 
57 
58 
59 
Dose 
gffl. 
27.2 
23.2 
25.5 
22.2 
19.4 
23.6 
23.5 
Molecular weights of backbones 
Upper limit  Lower  limit 
raol.  per  real.  par 
wt.  ceni  wl.  ¢ent 
65,000  8.5 13,000  11 
32,000 15  12,000  10 
64,000  5  38,000  25 
49,000  6  31,000  6 
49,000  6  31,0(E  6 
67,000  6  18,0(E  6 
67,000  6  18,00C  6 
Entire 
tool. 
wl. 
34,000 
24,000 
46,000 
38,60G 
38,600 
42,900 
42,900 
Molec- 
ular 
weight 
of side 
chains 
3,000 
3,000 
3,200 
3,000 
2,100 
2,500 
3,400 
Plasma volumes-dye  method 
Prein-  Postinfusion  fusion 
0 hr.  1 hr.  6 hr. 
ml  ml.  mL 
2680  3580  3100 
2780  3840  3220 
3190  3980  3790 
4170  4850  (lost) 
3390  4180  3800 
3050  3730  3480 
2880  3670  3600 
6 hr. 
expansion 
I hr; 
expansion 
X I00 
47 
42 
76 
52 
63 
90 
There seems to be a general  correlation between backbone size and rate of 
excretion.  Conjugate 52 is by far the most rapidly excreted in the urine and 
has  the smallest backbone.  Conjugate 55,  having  a  lower limit  of 38,000  is 
excreted less rapidly than Nos. 56, 57, 58, and 59 having lower limits of 18,000 
and 31,000.  The slow rate  of excretion of No. 51  is unexplained.  In several 
cases plasma and urine levels were followed to complete disappearance of the 
peptide, which occurs in both fluids approximately 1 week after infusion. 
It  appears  therefore  that  under  the  conditions  of  conjugation  used,  the 
minimal  favorable sizes for side chains  and  backbones are number  average 
molecular weight of 3,000 and 40,000-50,000  respectively, with  a  lower limit 
of 30000 for the backbone. 
As mentioned previously, this combination has several favorable qualities, 
particularly with respect to side chains. One aspect relates to the fact that side 
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esterification as described in methods,  whereas larger side chains can only be 
prepared by the use  of diazomethane for  the  esterification (2),  which  is not 
only more difficult but is also somewhat  hazardous,  especially in  large scale 
preparations.  Another  advantage  lies  in  the  easy  and  sharp  separation  of 
TABLE II 
Plasma Levels and Urinary Excretion of Polymers 
Polymer 
51 
52 
55 
56 
57 
58 
59 
Dose 
gm. 
27.2 
23.2 
25.5 
22.2 
19.4 
23.6 
23.5 
Hr. post 
infusion 
1 
6 
20 
1 
6 
20 
1 
6 
20 
1 
6 
20 
1 
6 
20 
1 
6 
20 
1 
6 
20 
Plasma level 
mg./ml. 
6.4 
5.3 
5.2 
3.8 
4.9 
3.8 
4.0 
3.3 
4.0 
3.0 
4.9 
3.3 
5.9 
4.6 
Total plasma 
polymer* 
gm. 
23 
16.5 
Per cent 
decrease from 
I-6 hrs. 
20 
12.2 
19.5 
14.4 
19.4 
28 
39 
26 
36 
16.7 
11.4  31 
18.2 
11.6 
21.6 
16.6  23 
Cumulative 
urinary 
excretion 
per cent total 
i,qused 
3.1 
8.8 
11.6 
6.6 
28.4 
41 
"3.9 
8.6 
16.5 
9.0 
15.7 
26.6 
10.3 
18.5 
29 
10.6 
17.4 
30 
10.6 
21 
30 
* Total plasma polymer -- mg./ml. X  plasma volume obtained by Evans blue method. 
conjugate from side chains of this size by alcohol fractionation as described in 
methods.  In contrast,  the side chains of number  average molecular weight of 
12,000 and larger are more difficult to separate from conjugate by this type of 
fractionation. 
In all the cases tested it is apparent that rather low levels of plasma polymers 
are associated with considerable plasma expansion volumes. The data relating 672  GLUTAMYL  PEPTIDE  POLYMERS 
TABLE III 
Fluid Retained in Plasma Polymer 
Polymer  Time  Plasma protein  Plasma polymer  Fluid retained/gin. 
polymer 
ml./gm. 
51 
52 
55 
56 
57 
58 
59 
]~r$. 
0 
1 
6 
2O 
0 
1 
6 
20 
0 
1 
6 
20 
0 
1 
6 
20 
0 
1 
6 
20 
0 
1 
6 
20 
0 
1 
6 
20 
gm./liter 
69.0 
48.5 
53.8 
57 
70 
51 
53 
66 
69.5 
52 
51 
60 
70.5 
54 
59.8 
62 
69 
54 
57.8 
63.8 
68 
48 
51.4 
58 
68.5 
50 
52.5 
61 
r~g./mt. 
0 
6.4 
5.3 
3.8 
0 
5.2 
3.8 
2.3 
0 
4.9 
3.8 
3.00 
0 
4.0 
3.3 
2.0 
0 
4.0 
3.0 
1.99 
0 
4.9 
3.3 
2.92 
0 
5.9 
4.6 
3.0 
47 
42 
46 
52 
64 
25 
51 
70 
46 
58 
49 
61 
54 
54 
38 
60 
74 
50 
46 
51 
37 
Average ..............................................................  51 
to the volume of fluid retained in the blood stream per gram of polymer are 
dv 
shown in Table III,  with  the  results  expressed  as  oncofic efficiency, dw--~( In 
Table IV similar data and results are given for mixed solutions of polymer and 
serum albumin in isotonic saline at pH 7.4, in which the range of concentrations 
of polymer is the same as were found in vivo. ROSENTHAL~  O'CONNELL~  AXELROD~ AND  BOVARNICK  673 
The method for arriving at the amount of fluid retained in the circulating 
plasma per graal of polymer present,  hereafter referred  to as the oncotic effi- 
ciency of the polymer, is as follows. The volume fraction of the plasma retained 
pt  in which p~ the plasma  by the plasma protein at any time, t, is made equal to Po' 
protein concentration at time t, and po =  the plasma protein concentration prior 
to the infusion. The oncotic efficiency, dw2, may then be expressed as follows:-- 
pt 
dv  Po  Po  -- pt 
in which 
dw~  y  Po y 
y  =  the grams of polymer per milliliter  of plasma. 
TABLE IV 
Oncotic E ficiency of Polymer in Mixed Solution with Serum A lbumin 
Concentration  Concentration  of  Osmotic  pressure  *bt2  d_~_v  dv 
of albumin  polymer  at 25°C.  dun  d-~ 
gra./liter 
51.3 
48.6 
46.0 
42.0 
40.5 
0 
gm./liter 
2.9 
3.8 
4.7 
5.6 
6.5 
18.1 
mm./Hg 
25.1 
25.8 
25.3 
24.0 
25.7 
27.9 
0.0107 
0.0125 
0.0111 
0.0097 
0.0118 
ml./gm. 
50.1 
50.2 
50.3 
51.7 
50.5 
57 
ml./gm. 
16.8 
16.7 
16.6 
16.9 
16.5 
* Average value of b~2 =  0.011. 
These equations are valid if we can make the following three assumptions. 
The first is that the osmotic pressure  of the plasma is constant in vivo.  The 
second is that the osmotic pressure  of the plasma protein,  especially that of 
the  serum albumin  which  accounts for  the major part  of  this pressure,  is 
independent of  its  concentration over  the  pertinent range  in  an  isosmotic 
mixed  solution  with the polymer.  The third is  that the composition  of the 
plasma protein is not sufficiently changed by the infusion to alter significantly 
its oncotic efficiency. 
The first assumption is easily accepted as true. The second has been shown 
by Scatchard (11) to be essentially true for mi~ed solutions of serum albumin 
and straight chain glutamyl polypeptide of number average molecular weight 
of 15,000. Using Scatchard's method, the development and application of which 
is  discussed  in  the  Appendix,  we  have  demonstrated  (Table  IV)  that  the 
second assumption is also valid for mixed isosmotic solutions of serum albumin 
and polymer of number average molecular weight of 48,000. The third assump- 
tion may not be strictly valid.  A comparison  of the plasma  protein dilution 674  GLUTAMYLPEPTIDE  POLYMERS 
values at 6 hours post infusion (Table III) with the expansion obtained by the 
Evans blue method at this time indicates compensatory migration of the pro- 
tein to the extravascular spaces. If, as seems to be the case with other expand- 
ers, the albumin preferentially migrates,  the composition and oncotic efficiency 
of the remaining plasma protein will have changed. It is felt, however, that the 
possible error  thus introduced is inconsequential,  and this seems to be borne 
out by the good agreement between the oncotic efficiency  values for the polymer 
in vivo and in vitro  (Tables  III and IV). 
The average  value of the oncotic efficiency of the polymer determined in 
vivo was 51 ml./gm., and that obtained in vitro, 52 ml./gm, at 25.0°C. (=  54 
ml./gm, at 37°C.), both being approximately three times that of serum albumin. 
It is of further interest that the oncotic effect of the polymer is additive to 
.400 
a[u 
.300  I  I  I  I  I  I  I 
0  I  2  3  4  5  6  7 
CONCENTRATION  OF  POLYMER  GRAMS  PER 
LITER 
FIo. 1. Ratio of osmotic pressure to concentration versus concentration of polymer  in 
1.0 M  sodium chloride at 25°C. 
that  of plasma  protein  and  of albumin,  with  no  indication of association 
between the polymer and proteins. 
The possibility that the high oncotic potency of the polymer might be due to 
low molecular weight rather than to Donnan effects is excluded by the molecu- 
lar weight of 48,000 calculated  from the osmotic pressure concentration curve 
of Fig. 1. 
This calculated molecular weight of 48,000 is, however, surprisingly low when 
it is remembered that the polymer backbone molecular weight was 46,000 and 
that side  chains  of molecular  weight  of 3,000 were presumably attached to 
approximately 25 per cent of the carboxyl group in the conjugation.  One pos- 
sible explanation is that this result may be due to error in the molecular weight 
determination caused  by the high  concentration of charges  associated  with 
the polymer. In this case 48,000 would be a minimum value. A second possi- 
bility is that the value of 48,000 is correct,  and that breakdown of the back- 
bone occurred in the polyazide stage. The azides are notoriously unstable and 
a Curtius rearrangement of an azide group would be apt subsequently to result ROSENTHAL~ O'CONNELL, AKELROD~ AND  BOVARNICK  675 
in a  break in the chain. There are about 300  azide groups in a  backbone of 
molecular weight of 40,000 and the rearrangement of 6 or 7 of these, if evenly 
distributed, would lead to final products of molecular weight of 50,000 if there 
were 25 per cent coverage with side chains of 3,000 molecular weight. Further 
work will be needed to determine the correct explanation of this value. Which- 
ever explanation is the correct  one, it  is  evident that  the  Donnan  activity 
of these polymers is a  real factor in relation to their usefulness as expanders. 
The clinical response in these seven trials was essentially uneventful. There 
was no significant increase in temperature or respiration, and a slight transient 
rise in pulse rate and blood pressure during the early period of expansion. Other 
than an expected increase in sedimentation rate and decrease in hematocrit 
value and red cell count following the infusion, there was no effect on the red 
cells. There was no significant change in platelet counts, clotting, or bleeding 
times. In two cases there was a rise in white count to 14,000 at 6 and 24 hours, 
and in two cases there were vague mild complaints of abdominal distress and 
some anorexia starting the day following the infusion and continuing intermit- 
tently for 2 or 3 days. Since these were not new symptoms in these patients, 
their significance is difficult to evaluate. The possibility of allergic manifestation 
is of course present but will require larger numbers of tests for final evaluation. 
In  some  35  previous  infusions with  peptide  and  polymer prepared  in  our 
laboratory no similar  complaints  or other  evidence of sensitivity have  been 
encountered,  and  in  a  small  series  of observations no  evidence of positive 
precipitation  test or complement fixation tests between the peptide or con- 
jugate and either preinfusion or 2 to 3 week posfinfusion sera have been found. 
More extensive clinical and immunological studies are in progress.  Should any 
positive allergenic properties of the conjugate manifest themselves, the recent 
synthesis of alpha (12,  13) and  gamma (14)  glutamyl pepfides offer the  pos- 
sibility of preparation of synthetic conjugates composed of homogeneous d- 
or l-glutamic acid, either of which might be immunologically inert in humans 
should the bacterial peptide, which is a  mixture of D-, L-glutamic acid prove 
otherwise. The bacterial peptide is economically attractive, however, thanks 
to  the excellent fermentation yields made available by the studies of House- 
right and Thome and their associates (15)  who have developed conditions of 
deep culture on modified Santon's medium which lead to yields as high as 
10 to 16 gm. of peptide per liter of deep culture. 
SUMMARY 
A series of polymers of polyglutamic acid have been tested as plasma volume 
expanders. The results indicate that those polymers prepared from backbones 
of 40,000  molecular weight or over and side chains of 3,000  molecular weight 
or over, will have plasma volume retention half-life of 15 hours or longer. 
Measurements of the oncotic efficiency of these polymers in ~i~o indicated a 676  GLUTAMYLPEPTIDE  POLYMERS 
blood stream fluid retention of approximately 51 ml./gm, of polymer.  Similar 
measurements of polymer-serum albumin solutions in vitro showed a retention 
of 52 ml./gm, of polymer. 
The clinical response to infusion of solutions of these polymers indicated no 
untoward pharmacological properties.  Although the number of trials presented 
is too small for ultimate conclusion regarding either the physiological or clinical 
effects of these polymers, they do provide a strong indication of the desirability 
of further clinical testing of this polymer and a sound basis on which to plan 
the larger scale preparation of polymer. Both measures are currently under way. 
APPENDLX 
dv 
The oncotic efficiency, --  of a  non-diffusible substance in  solution has been defined 
dw2(pj~) 
by Scatchard (11) "as the number of cc.'s added to an infinite volume of the solution for 
each gram of the substance added when the osmotic pressure, the quantities of all  other 
non-diffusible substances inside the membrane and the concentration outside the membrane 
of each diffusible  substance is kept constant." He further states that in a mixed solution of 
two non-diffusible substances, "in the concentratibn range in which the osmotic pressure is 
a  quadratic function of the total concentration when the ratio Cl is kept constant,  the os- 
c2 
motic pressure is expressed by the relation:-- 
"(1)  p  =, alcl -J- a2ca -J- bncl  ~ -J- b2~c2  ~ -~- 2b12c1¢2 
in which 
"p  =  ram. of Hg 
"cI =  gin. of first non-diffusible substances per kg. of water (albumin) 
"c2  =  gin. of second non-diffusible per kg. of water (polymer), and 
"al, 02, b11, b22, and b12 are constants." 
The significance  of these constants is best understood in relation to their determination. 
The osmotic pressure, p, of a  single non-diffusible substance such as serum albumin, or the 
polymer, in isotonic salt solution can be defined by the relation 
(2) p  =  ac -{- bc  ~ or p- =  a  ~  be,  in which c equals the concentration of the non-diffusi- 
C 
ble solute in grams per kilogram of water. If -p is plotted as ordinate against  ¢, a  curve is 
c 
obtained whose intercept with the ordinate, where c is at 0, gives the value of the constant 
'a'. The constant 'a' relates to the molecular weight of the solute as follows:-- 
~  RT 
aW  =  0-, where R  is the usual  gas constant, T is  the absolute  temperature V°~, is the 
V~ 
volume of the solution containing 1 kg. of water when c is 0, and W is the number average 
molecular weight of the solute in question (16-18). 
The constant b is determined as the slope of the curve and represents the sum of three 
main components. These are  (a)  the effect of ionized groups and their associated charges, 
which effects account for the Donnan phenomena; (b)  the interaction effects between the 
non-diffusible component and ionized salts present; and (c) the effects of interaction among 
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The salt-protein interaction component is usually quite small. These three are combined in 
the one constant, b, which is a  quadratic term and is determined in a  salt-protein solution. 
The values Of the 'a' and 'b' constants for serum albumin (al and b11) are given by Scat- 
chard  (11)  as 0.267  and 0.00256  respectively.  The value of 0.384 for the polymer 'a' con- 
stant,  as  is  obtained  from p- vs. c curve shown in Fig.  1. The data for this curve were ob- 
c 
tained with a  1.0 ~  NaC1 solution of polymer. In this concentration of salt the Donnan ef- 
fects of the polyelectrolyte are suppressed so that the limiting value of p- shouid reflect only 
c 
the molecular weight of the polymer. The value of the b polymer constant, b22, was obtained 
from measurements of the colloid osmotic pressure of the polymer in isotonic saline at pH 
7.4 which corresponds more closely to physiological conditions• The data are given in Ta- 
ble V. The positive deviations of osmotic pressure at the higher and lower concentrations of 
polymer are similar to those noted by Scatchard in measurements with the lower molecular 
TABLE  V 
Osmotic Pressure of Polymer in Isotonic Saline 
Concentration  Osmotic pressure 
gm./liter 
2.50 
5.02 
8.14 
9.93 
11.86 
13.95 
16.10 
18.14 
mm.Hg. 
1.90 
3.55 
5.81 
8.26 
11.2 
14.7 
20.4 
27.9 
weight straight chain polyglutamic acid  (11).  Using these data and the independently de- 
termined value of a2, Equation 2 can be solved for b22, giving a value of 0.046. 
In mixed solutions of two non-diffusible components, the term ac in Equation 2 becomes 
]~zca~ct¢  and be  2 becomes  ]~ba~rc~cJv,  and  Equation  2  expands into Equation 1. The 
first four constants of Equation I  are given above. The b19. term can now be determined in 
Equation 1 by measurements of p for the mixed solution of the polymer and albumin. Values 
of bls are given in Table IV. The average value was used  for calculations  of oncotic effi- 
dr 
caency, V-- • 
•  t~W2 
dr 
An equation expressing oncotic efficiency of the polymer, d~v2 in the above terms can now 
be derived. By substituting wl and w2 for ¢1 and c~ in Equation 1, and  differentiating with 
wl and p as constants, the expression 
dv  a2 .+- 2h2 cz -I- 2b= cs 
(3)  --  ffi  100o 
dw2  al cl -k a~ c2 -k 2but12 q- 2b.. c2  s -k 4bn cl c2 
is obtained. 678  GLUTAMYL PEPTIDE POLYMERS 
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